Medical Weight Loss

Tirzepatide vs. Semaglutide: How a Physician Chooses Between Them

The first head-to-head trial gave tirzepatide the edge on weight reduction. That does not automatically make it the right medication for every patient, and here is what a physician weighs before prescribing either one.

Tirzepatide and semaglutide compared for medical weight loss at Aevum Restorative Wellness in Houston

Key takeaways

  • In the first head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide over 72 weeks - about 20% of body weight compared with about 14%.
  • Averages describe groups, not individuals. Some patients respond better to semaglutide, and response varies considerably from person to person.
  • Both medications share the same class of gastrointestinal side effects, which are most common during dose escalation.
  • Cost, supply, tolerability, other medical conditions and prior treatment history all influence the choice as much as trial data does.
  • Neither medication is a standalone treatment. Both work alongside nutrition, resistance training and ongoing clinical follow-up.

Most people arrive at this question having already read that one of these medications is better than the other. The honest answer is more useful than that, and it starts with what the evidence actually shows before moving to the part that matters more - which one fits the patient sitting in front of us.

What the head-to-head trial found

Until recently, comparing these two medications meant comparing separate trials with different participants and different designs, which is a weak way to answer the question. That changed with SURMOUNT-5, the first trial to compare them directly.

The trial randomly assigned 751 adults with obesity, but without type 2 diabetes, to the maximum tolerated dose of either tirzepatide or semaglutide for 72 weeks. At the end, average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. In practical terms that was roughly 50 pounds versus roughly 33 pounds. Waist circumference fell further in the tirzepatide group as well.

Tirzepatide also produced more patients reaching the larger thresholds. More than 80% of the tirzepatide group lost at least 10% of their body weight, compared with about 61% of the semaglutide group.

So on the primary question the trial was designed to answer, tirzepatide won, and it is not a close result.

Why the trial result is not the whole answer

Three things are worth understanding about that number before treating it as a verdict.

It is an average. Individual responses in both groups ranged widely. Some patients on semaglutide lost more than the tirzepatide average, and some patients on tirzepatide lost very little. A 6.5 percentage-point difference between group means says almost nothing about what any one person will experience.

The trial was open-label. Participants and investigators knew which medication was being given, because the trial used the original manufacturer packaging for both drugs. That is a real limitation, though the results line up with what blinded trials of each drug separately had already shown.

The comparison was between specific doses. Tirzepatide was given at 10 or 15 mg and semaglutide at 1.7 or 2.4 mg. Those are the maximum approved doses for weight management, so the comparison is fair, but it is a comparison of those doses rather than of the molecules in the abstract.

How the two medications differ mechanically

Semaglutide is a GLP-1 receptor agonist. It acts on a single receptor pathway involved in appetite regulation, gastric emptying and insulin secretion.

Tirzepatide acts on two receptors - GLP-1 and GIP. The prevailing explanation for the difference in results is that GIP receptors are expressed in brain regions that regulate food intake in a pattern that does not fully overlap with GLP-1 receptors, so acting on both may produce a larger effect than acting on either alone.

That is a mechanistic hypothesis rather than a settled fact, but it is consistent with what the trials show.

Side effects, and what actually causes people to stop

Both medications produce gastrointestinal side effects - nausea, vomiting, diarrhea, constipation. In SURMOUNT-5 most were mild to moderate and clustered during dose escalation, which is the period when the dose is being stepped up.

One finding runs against the assumption that the stronger drug is the harder one to tolerate: gastrointestinal side effects severe enough to stop treatment occurred more often with semaglutide (5.6%) than with tirzepatide (2.7%).

Both carry a boxed warning regarding thyroid C-cell tumors observed in rodents, and neither is appropriate for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis, gallbladder disease and, in patients with retinopathy, changes in diabetic eye disease are recognized concerns that warrant discussion before starting. Neither medication is used during pregnancy or while trying to conceive.

What we weigh when choosing

Trial data sets the starting point. It rarely settles the decision on its own. In practice these are the considerations that move it:

Prior response. A patient who has already taken semaglutide and tolerated it poorly, or plateaued early, is a different case from someone starting fresh.

Other medical conditions. Existing cardiovascular disease, kidney disease, a history of pancreatitis or gallbladder disease, or diabetic retinopathy all change the calculation.

Tolerability and life circumstances. Someone who cannot afford weeks of nausea during a demanding period at work may do better starting lower and escalating more slowly, regardless of which drug is chosen.

Cost and supply. These medications are expensive and supply has been inconsistent. A medication a patient cannot reliably obtain or afford for a year is not the better medication for that patient, whatever the trial says.

Whether medication is the right first step at all. Sometimes it is not. Untreated sleep apnea, certain medications that promote weight gain, thyroid disease and alcohol intake all deserve attention before or alongside a prescription.

What these medications cost at Aevum

We publish our pricing because guessing at cost wastes everyone's time.

Tirzepatide for non-members starts at $400 per month at lower doses and $500 per month at higher doses. Members receive tiered discounts depending on membership level.

Aevum does not bill insurance. Some patients have coverage through their own plans and can pursue reimbursement independently, but coverage for weight management medications is inconsistent and frequently denied, so we would rather you plan around the published price than around a hoped-for approval.

What medication does not do on its own

Both drugs reduce appetite. Neither builds muscle, improves sleep, or teaches anyone how to eat.

Weight lost without attention to protein intake and resistance training includes a meaningful proportion of lean mass, which matters for metabolic rate and for function later in life. And when these medications are stopped, weight regain is common. That is not a failure of the patient or the drug - it is what happens when a treatment addressing an ongoing physiologic process is withdrawn.

This is why we treat the prescription as one component of a program rather than the program itself.

The short version

If the only question is which medication produces more weight loss on average, the current evidence favors tirzepatide. If the question is which medication is right for you, that depends on your history, your other conditions, what you can tolerate, what you can sustain, and what we find in your labs.

That is a conversation, not a comparison table.

Frequently asked questions

Is tirzepatide better than semaglutide?

In the only head-to-head trial to date, tirzepatide produced greater average weight reduction over 72 weeks. That is a real finding, but it describes group averages rather than individual outcomes. Some patients do better on semaglutide. The right medication depends on your medical history, tolerability, cost and prior treatment response.

Can I switch from one to the other?

Often, yes, and it is a common reason patients come to us. Switching involves restarting dose escalation rather than transferring directly across at an equivalent dose, and it should be supervised. Whether switching is appropriate depends on why the first medication is not working.

Will my insurance cover these medications?

Aevum does not bill insurance. Coverage for weight management medications through individual plans is inconsistent, and denials are common even when the prescription is clinically appropriate. Our published pricing is what you pay.

What happens if I stop taking it?

Weight regain is common after stopping, and studies of both medications show this consistently. Planning for what happens after the medication phase is part of the program, not an afterthought.

How quickly will I see results?

Both medications are escalated gradually over months, so early weeks are usually about tolerance rather than results. Meaningful change typically becomes apparent over several months. Results vary between individuals, and there is no way to predict an individual response in advance.

Do I need labs before starting?

Yes. We evaluate metabolic markers, thyroid function, kidney and liver function and other relevant values before prescribing, both to identify contributing causes and to establish a baseline for monitoring.

References

  1. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394
  2. Mamas MA, Bays H, Li R, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. Eur Heart J Open. 2025;5(5):oeaf117. doi:10.1093/ehjopen/oeaf117
Xinwei Liu

Xinwei Liu

Medical Director

Dr. Xinwei Liu is the Medical Director at Aevum Restorative Wellness. He is board-certified in Emergency Medicine, completed residency at Kaiser Permanente San Diego, and earned his medical degree at the University of Central Florida.

Read full profile

Medically reviewed

Xinwei Liu

MD

October 15, 2026

October 15, 2026

This article is for general education and is not medical advice. Individual results vary. Speak with a licensed clinician about your own situation.

Next step

Lab-guided care starts with a conversation, not a product.

Explore medical weight loss in HoustonBook a Consultation

Aevum Restorative Wellness

1224 Houston Avenue, Suite 101, Houston, TX 77007

713-280-1551

care@aevumrestorative.com

Monday to Friday, 10am to 7pm; Saturday and Sunday, 9am to 5pm